CN-121987626-A - Use of ergothioneine formulations for the preparation of products for remodelling the methylation profile of inflammation-associated DNA and/or reducing the epigenetic age

Abstract

The invention relates to application of ergothioneine preparation in preparing products for remodelling inflammation-related DNA methylation spectrum and/or reducing epigenetic age, the invention develops new application of ergothioneine, provides research basis for wide application, and also develops a brand-new strategy for remodelling inflammation-related DNA methylation spectrum and/or reducing epigenetic age, the invention discovers that ergothioneine has remarkable effects on remodelling DNA methylation spectrum related to inflammation and reducing epigenetic age, and is particularly effective in correcting methylation rate drift of immune regulation, inflammation and senescence-related gene loci so as to effectively reduce epigenetic age and inflammation age.

Inventors

• LIU WEI
• DING WEI
• CAO JUAN
• ZHU YUAN
• XIAO GUOHUA

Assignees

• 江苏仅三生物科技有限公司

Dates

Publication Date

20260508

Application Date

20260331

Claims (8)

1. 1. Use of a ergothioneine formulation for the preparation of a product for remodelling the methylation profile of inflammation-associated DNA and/or reducing the epigenetic age.
2. 2. The use according to claim 1, wherein the active ingredient in the ergothioneine preparation comprises any one or a combination of at least two of ergothioneine, a physiologically acceptable salt, acid, ester, polymer or derivative thereof.
3. 3. The use according to claim 1, wherein the formulation of ergothioneine comprises a powder, a tablet, a granule, a capsule, a solution, an emulsion or a suspension.
4. 4. The use according to claim 1, wherein the remodelling of the inflammation-associated DNA methylation profile specifically comprises preventing, delaying or reversing abnormal methylation of promoter and enhancer regions of genes associated with senescence-associated secretion phenotypes.
5. 5. The use according to claim 4, wherein the gene comprises any one or a combination of at least two of nuclear factor-kappa B, NLRP, interleukin-6, tumor necrosis factor-alpha, C-reactive protein, plasminogen activator inhibitor-1, CXC chemokine ligand 9.
6. 6. The use of claim 1, wherein the data source for obtaining the DNA methylation profile comprises any one or a combination of at least two of bisulfite sequencing, methylation gene chip, targeted methylation sequencing, or single molecule real-time sequencing techniques.
7. 7. The use according to claim 1, wherein the epigenetic age is calculated using an epigenetic clock algorithm.
8. 8. The use according to claim 7, wherein the epigenetic clock algorithm comprises the step of calculating apparent age based on a multivariate predictive model constructed of methylation levels of genome-wide or specific groups of genome CpG sites.

Description

Use of ergothioneine formulations for the preparation of products for remodelling the methylation profile of inflammation-associated DNA and/or reducing the epigenetic age Technical Field The invention belongs to the technical field of functional foods and epigenetic science, relates to a new application of ergothioneine, and in particular relates to an application of ergothioneine preparation in preparing a product for remodelling DNA methylation spectrum related to inflammation and/or reducing epigenetic age. Background Ergothioneine (L-Ergothioneine, EGT) is an extremely rare and naturally occurring sulfur-containing histidine derivative proposed by Bruce Ames yard as "longevity vitamin (Longevity Vitamin)". The essential difference from common antioxidants such as vitamin C which rely on passive diffusion is that mammals retain the unique and highly specific transmembrane transporter, OCTN1 (encoded by SLC22A4 gene), for ergothioneine during long evolution. Depending on the powerful active transport mechanism of OCTN1, ergothioneine can penetrate cell membranes and is highly enriched in oxidative stress disaster areas such as mitochondria and cell nuclei. The nature of senescence is not just the passage of time, but rather the uncontrolled pattern of genomic expression. Senescent cells develop a "senescence-associated secretory phenotype (SASP)", with continued secretion of pro-inflammatory factors (e.g., IL-6, CXCL9, etc.). Studies have shown that the driving force for this SASP stems from drift in DNA methylation patterns. DNA methylation, an epigenetic phenomenon, has been shown to be involved in biological age prediction. Currently, the "epigenetic clock (EPIGENETIC CLOCK)", constructed by detecting the methylation level of specific CpG sites throughout the genome, has been recognized as the gold standard for quantifying biological age and the degree of inflammatory aging. In the prior art (US 11534426B 1), based on nematode models, ergothioneine was disclosed to trigger autophagy in the modulation of insulin signaling pathways and down-regulation of the cpr-1 gene, with the endpoint being macroscopic and unquantifiable "extended health". In the prior art, the application of ergothioneine in removing downstream Reactive Oxygen Species (ROS) is disclosed, but the application of ergothioneine in regulating the methylation degree of senescence-or inflammation-related genes is relatively less, so how to provide a product capable of effectively remodelling the DNA methylation spectrum of inflammation-related gene loci and/or reducing the epigenetic age has wide application value. Disclosure of Invention In view of the deficiencies of the prior art, it is an object of the present invention to provide the use of ergothioneine formulations for the preparation of products for reshaping the methylation profile of inflammation-associated DNA and/or for reducing the epigenetic age. In order to achieve the aim of the invention, the invention adopts the following technical scheme: In a first aspect, the invention provides the use of a ergothioneine preparation for the preparation of a product for remodelling the methylation profile of inflammation-associated DNA and/or reducing the epigenetic age. The invention develops the new application of ergothioneine, provides a research basis for the wide application of the ergothioneine, and also develops a brand-new strategy for remodelling the DNA methylation spectrum related to inflammation and/or reducing the epigenetic age, the invention discovers that ergothioneine has remarkable effects on remodelling DNA methylation spectrum related to inflammation and reducing epigenetic age, and is particularly effective in correcting methylation rate drift of immune regulation, inflammation and senescence-related gene loci so as to effectively reduce epigenetic age and inflammation age. Preferably, the active ingredient in the ergothioneine formulation comprises any one or a combination of at least two of ergothioneine, a physiologically acceptable salt, acid, ester, polymer or derivative thereof. Preferably, the formulation of the ergothioneine preparation comprises powder, tablet, granule, capsule, solution, emulsion or suspension. Preferably, the remodelling inflammation-associated DNA methylation profile specifically includes abnormal methylation of promoter and enhancer regions that prevent, delay or reverse aging-associated secretory phenotype associated genes. Preferably, the gene comprises any one or a combination of at least two of nuclear factor-kappa B, NLRP, interleukin-6, tumor necrosis factor-alpha, C-reactive protein, plasminogen activator inhibitor-1, CXC chemokine ligand 9. Preferably, the data sources from which the DNA methylation profile is obtained include any one or a combination of at least two of bisulfite sequencing, methylation gene chip, targeted methylation sequencing, or single molecule real-time sequencing techniques. Preferably, the epigenetic age